GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Share News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Polar Capital Global Healthcare Lags Behind Benchmark In First Half

Fri, 10th May 2019 09:36

LONDON (Alliance News) - Polar Capital Global Healthcare Trust PLC said on Friday it lagged against its benchmark for the first half of its financial year, as the healthcare trust underperformed in the period.

For the six months to the end of March, the trust's net asset value negative return was 3.0%, compared to the 2.3% negative return by the MSCI ACWI/Healthcare Index in sterling terms, with dividends reinvested.

Net asset value per share as at March 31 was 233.53 pence, up from 183.00p the same date the year before, but down from 241.91p at the end of September.

Polar Capital's share price at the end of March was 216.00p, reflecting a discount to net asset value of 7.5%, widened from 6.1% the year before.

Shares in Polar Capital Global Healthcare were down 1.0% on the day Friday at 203.50 pence, having fallen 5.8% since the period-end.

The trust said that the overall healthcare market "modestly underperformed", with major sell-offs in October and December due to trade friction, slowing global growth, as well as political uncertainties.

Detractors within the trust's portfolio includes Diurnal Group PLC, which reported that its congenital adrenal hyperplasia treatment product Chronocort failed to meet its primary objective in its phase three trial.

Another detractor was Consort Medical PLC, due to delays in some of its customer projects.

However, stocks that performed well were Merck & Co Inc, with strong momentum in its immuno-oncology and vaccines businesses, and Renalytix AI PLC, due to progress in the development of its AI-enabled product for treating kidney diseases.

"While backward looking, the temperamental, almost nervous nature of the market further underpins our view that large-cap healthcare companies should be a relatively attractive place to invest in the near to medium term," Polar Capital Global Healthcare said.

"With technology at the fore, we continue to believe we can find companies within our investment universe that are capable of delivering mid to high single-digit, organic, top-line growth, operating leverage as well as high single to low double-digit total shareholder returns," the trust added.

More News
11 Oct 2021 19:51

TRADING UPDATES: Baron Oil boosts P2478 stake amid Upland farmout pact

TRADING UPDATES: Baron Oil boosts P2478 stake amid Upland farmout pact

Read more
14 Sep 2021 17:46

TRADING UPDATES: Strong annual results from Springfield, Fiske

TRADING UPDATES: Strong annual results from Springfield, Fiske

Read more
13 Sep 2021 20:23

IN BRIEF: Diurnal's Efmody adrenal treatment launches in UK

IN BRIEF: Diurnal's Efmody adrenal treatment launches in UK

Read more
7 Sep 2021 16:25

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
1 Sep 2021 19:34

TRADING UPDATES: Power Metal hits "bullseye"; Instem makes acquisition

TRADING UPDATES: Power Metal hits "bullseye"; Instem makes acquisition

Read more
28 Jul 2021 18:07

TRADING UPDATES: United Oil & Gas in North Sea sale; Trifast confident

TRADING UPDATES: United Oil & Gas in North Sea sale; Trifast confident

Read more
12 Jul 2021 10:10

Diurnal agrees special protocol with FDA for Chronocort study

(Sharecast News) - Specialty pharmaceutical company Diurnal announced on Monday that the US Food and Drug Administration (FDA) has agreed a special protocol assessment (SPA) for 'Chronocort', or modified-release hydrocortisone, for the design, endpoints and statistical analysis approach of a pivotal study of the product, for the treatment for congenital adrenal hyperplasia (CAH).

Read more
2 Jul 2021 10:02

Diurnal gets UK approval for 'Efmody' treatment

(Sharecast News) - Speciality pharmaceutical company Diurnal Group announced on Friday that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorisation for 'Efmody', or hydrocortisone modified-release hard capsules, as treatment for adult and adolescent patients with the rare congenital adrenal hyperplasia (CAH) condition.

Read more
2 Jul 2021 10:01

Diurnal gets UK approval for Efmody drug following EU authorisation

Diurnal gets UK approval for Efmody drug following EU authorisation

Read more
29 Jun 2021 17:10

TRADING UPDATES: Gaming Realms BetMGM deal; Argo bitcoin-backed loan

TRADING UPDATES: Gaming Realms BetMGM deal; Argo bitcoin-backed loan

Read more
1 Jun 2021 20:24

TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets

TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets

Read more
28 May 2021 19:41

TRADING UPDATES: Odyssean IT swings to profit; BMO Cap ups dividend

TRADING UPDATES: Odyssean IT swings to profit; BMO Cap ups dividend

Read more
12 May 2021 15:30

IN BRIEF: Diurnal extends Citrine licensing deal for Efmody in China

IN BRIEF: Diurnal extends Citrine licensing deal for Efmody in China

Read more
23 Apr 2021 12:56

IN BRIEF: Diurnal gets another patent for adrenal insufficiency asset

IN BRIEF: Diurnal gets another patent for adrenal insufficiency asset

Read more
23 Apr 2021 10:31

Diurnal granted European patent for Alkindi

(Sharecast News) - Hormonal disease-focussed speciality pharmaceutical company Diurnal Group announced the grant of a patent for 'Alkindi', or hydrocortisone granules in capsules for opening, by the European Patent Office on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.